Thyroid Gland Adenocarcinoma — Trials

Thyroid Gland Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

195 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 43
Recruiting: 17
Ph III recruiting: 4
Growth YoY: —
Industry share: 7%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 25.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (13)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03753919	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial(DUTHY)	terminated	Phase 2	79	Grupo Espanol de Tumores NeuroendocrinosOTHER	1	Mar 11, 2026	clinicaltrials
NCT04985604	Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors	terminated	Phase 2	23	Day One Biopharmaceuticals, Inc.INDUSTRY	7	Oct 2, 2025